Onivyde for the therapy of multiple solid tumors

被引：125

作者：

Zhang, Haijun ^{[1
]}

机构：

[1] Southeast Univ, Zhongda Hosp, Sch Med, Dept Oncol, 87 Dingjiaqiao, Nanjing 210009, Jiangsu, Peoples R China

来源：

ONCOTARGETS AND THERAPY | 2016年 / 9卷

基金：

中国国家自然科学基金;

关键词：

irinotecan; PEP02; MM-398; Onivyde; drug delivery system; tumor therapy; METASTATIC COLORECTAL-CANCER; MAGNETIC FE3O4 NANOPARTICLES; RANDOMIZED PHASE-II; PANCREATIC-CANCER; NANOLIPOSOMAL IRINOTECAN; 2ND-LINE CHEMOTHERAPY; GASTRIC-CANCER; GAMBOGIC ACID; PEP02; MM-398; GEMCITABINE;

D O I：

10.2147/OTT.S105587

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Drug delivery system based on nanobiotechnology can improve the pharmacokinetics and therapeutic index of chemotherapeutic agents, which has revolutionized tumor therapy. Onivyde, also known as MM-398 or PEP02, is a nanoliposomal formulation of irinotecan which has demonstrated encouraging anticancer activity across a broad range of malignancies, including pancreatic cancer, esophago-gastric cancer, and colorectal cancer. This up-to-date review not only focuses on the structure, pharmacokinetics, and pharmacogenetics of Onivyde but also summarizes clinical trials and recommends Onivyde for patients with advanced solid tumors.

引用

页码：3001 / 3007

页数：7

共 34 条

[1]

AKIMOTO K, 1994, CHEM PHARM BULL, V42, P2135, DOI 10.1248/cpb.42.2135

[2] Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients [J].

Chang, T. C. ;

Shiah, H. S. ;

Yang, C. H. ;

Yeh, K. H. ;

Cheng, A. L. ;

Shen, B. N. ;

Wang, Y. W. ;

Yeh, C. G. ;

Chiang, N. J. ;

Chang, J. Y. ;

Chen, L. T. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) :579-586

[3] PEPCOL: A randomized noncomparative phase II study of PEP02 (MM-398) or irinotecan in combination with leucovorin and 5-fluorouracil as second-line therapy in patients with unresectable metastatic colorectal cancer-A GERCOR Study. [J].

Chibaudel, Benoist ;

Maindrault-Goebel, Frederique ;

Andre, Thierry ;

Bachet, Jean Baptiste ;

Louvet, Christophe ;

Khalil, Ahmed ;

Dupuis, Olivier Jean Marie ;

Hammel, Pascal ;

Garcia, Marie Line ;

Bennamoun, Mostefa ;

Brusquant, David ;

Arbaud, Claire ;

Wang, Yi-Wen ;

Yeh, Grace ;

Bonnetain, Franck ;

De Gramont, Aimery .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)

[4] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].

Conroy, Thierry ;

Desseigne, Francoise ;

Ychou, Marc ;

Bouche, Olivier ;

Guimbaud, Rosine ;

Becouarn, Yves ;

Adenis, Antoine ;

Raoul, Jean-Luc ;

Gourgou-Bourgade, Sophie ;

de la Fouchardiere, Christelle ;

Bennouna, Jaafar ;

Bachet, Jean-Baptiste ;

Khemissa-Akouz, Faiza ;

Pere-Verge, Denis ;

Delbaldo, Catherine ;

Assenat, Eric ;

Chauffert, Bruno ;

Michel, Pierre ;

Montoto-Grillot, Christine ;

Ducreux, Michel .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825

[5] Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy [J].

Drummond, DC ;

Noble, CO ;

Guo, ZX ;

Hong, K ;

Park, JW ;

Kirpotin, DB .

CANCER RESEARCH, 2006, 66 (06) :3271-3277

[6] UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice [J].

Etienne-Grimaldi, Marie-Christine ;

Boyer, Jean-Christophe ;

Thomas, Fabienne ;

Quaranta, Sylvie ;

Picard, Nicolas ;

Loriot, Marie-Anne ;

Narjoz, Celine ;

Poncet, Delphine ;

Gagnieu, Marie-Claude ;

Ged, Cecile ;

Broly, Franck ;

Le Morvan, Valerie ;

Bouquie, Regis ;

Gaub, Marie-Pierre ;

Philibert, Laurent ;

Ghiringhelli, Francois ;

Le Guellec, Chantal .

FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 (03) :219-237

[7]

Garcia-Carbonero R, 2002, CLIN CANCER RES, V8, P641

[8]

Hoff D. V., 2014, Annals of Oncology, V25, pii105, DOI [10.1093/annonc/mdu193.3, DOI 10.1093/ANNONC/MDU193.3]

[9] Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion [J].

Kalra, Ashish V. ;

Kim, Jaeyeon ;

Klinz, Stephan G. ;

Paz, Nancy ;

Cain, Jason ;

Drummond, Daryl C. ;

Nielsen, Ulrik B. ;

Fitzgerald, Jonathan B. .

CANCER RESEARCH, 2014, 74 (23) :7003-7013

[10] Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression [J].

Kang, Min H. ;

Wang, Jing ;

Makena, Monish R. ;

Lee, Joo-Sang ;

Paz, Nancy ;

Hall, Connor P. ;

Song, Michael M. ;

Calderon, Ruben I. ;

Cruz, Riza E. ;

Hindle, Ashly ;

Ko, Winford ;

Fitzgerald, Jonathan B. ;

Drummond, Daryl C. ;

Triche, Timothy J. ;

Reynolds, C. Patrick .

CLINICAL CANCER RESEARCH, 2015, 21 (05) :1139-1150

← 1 2 3 4 →